Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy

Figure 3 Draft proposal of a treatment strategy for advanced hepatocellular carcinoma. (1) For advanced hepatocellular carcinoma (HCC) patients without macroscopic vascular invasion and Child-Pugh A, the first-line treatment should be sorafenib, while second-line treatments should be either regorafenib or hepatic arterial infusion chemotherapy (HAIC); (2) For advanced HCC patients with macroscopic vascular invasion and Child-Pugh A, the first-line treatment should be HAIC, and the second-line treatments should be either sorafenib or experimental treatment in clinical trials; (3) For advanced HCC patients with Child-Pugh B, the first-line treatment should be HAIC, and the second-line treatment should be clinical trials.